- Home
- EKSO vs HURA Comparison
EKSO vs HURA Comparison
Compare EKSO & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EKSO | HURA |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 35.5M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | EKSO | HURA |
|---|---|---|
| Price | $10.11 | $1.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.50 | ★ $10.00 |
| AVG Volume (30 Days) | 154.8K | ★ 3.4M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.23 | N/A |
| Revenue Next Year | $7.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.41 |
| 52 Week High | $13.27 | $4.41 |
Technical Indicators
Market Signals| Indicator | EKSO | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 73.93 |
| Support Level | $8.71 | $1.56 |
| Resistance Level | $10.76 | $2.75 |
| Average True Range (ATR) | 1.05 | 0.28 |
| MACD | -0.19 | 0.07 |
| Stochastic Oscillator | 29.52 | 86.15 |
Price Performance
Historical ComparisonAbout EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.